ARTICLE | Clinical News
Dexanabinol (HU-211): Began Phase III study
January 16, 2001 8:00 AM UTC
Pharmos Corp. (PARS; EASD:PHRM), Iselin, N.J. Product: Dexanabinol (HU-211) Business: Neurological Therapeutic category: Receptor antagonist, Neurotransmission Target: NMDA receptors Description: Synt...